Revolution Medicines has appointed Dr Stephen Kelsey as its senior leader in a role that will see him focus on advancing medical agendas to aid cancer patients.
Most recently president at Onkaido Therapeutics, Kelsey’s specialty lies within oncology and development.
He said: “Revolution Medicines uses a novel approach to drug discovery that enables it to tackle promising cancer targets that have been difficult to access by convention means.
“I’m impressed with the quality of the company’s research team, founders and advisors, and am keen to help bring the next generation of transformational therapeutics to cancer patients.”
Prior to his time at Onkaido Therapeutics, Kelsey has served in several senior positions at Medivation, Generon and Genentech, where he held the role of vice president, haematology and oncology.
Mark Goldsmith, president and chief executive officer of Revolution Medicines, said: “Steve has had a distinguished career in oncology as both an academic clinician and a drug development executive in the biotechnology industry.
“He is superbly positioned to help us by deliver great benefit to cancer patients by advancing our lead programmes and creating a sustainable product pipeline that harnesses frontier oncology targets.”